Home › Trials › NCT06848348

Treatment of neuropathic pain caused by chemotherapy with Halneuron

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Phase 2 Interventional Dogwood Therapeutics Inc. · NCT06848348

This study is testing if a single injection of Halneuron can help relieve neuropathic pain caused by chemotherapy in patients who have experienced this type of pain.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years and up
SexAll
SponsorDogwood Therapeutics Inc. Industry-sponsored
Drugs / interventionschemotherapy
Locations24 sites (Sheffield, Alabama and 23 other locations)
Trial IDNCT06848348 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and efficacy of a single subcutaneous administration of Halneuron in patients suffering from chemotherapy-induced neuropathic pain (CINP). It is a randomized, interventional Phase 2 trial that aims to determine how well Halneuron alleviates pain compared to a placebo. Participants must have a history of neuropathic pain linked to specific chemotherapy agents, namely platinum and/or taxanes, and must not have active disease progression. The study will help assess whether Halneuron can provide relief for patients experiencing this type of pain.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who have neuropathic pain attributed to platinum or taxane chemotherapy.

Not a fit: Patients with neuropathic pain from causes other than platinum or taxane chemotherapy will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce neuropathic pain for patients undergoing chemotherapy.

How similar studies have performed: While this approach is being tested in this specific context, similar studies have shown promise in treating neuropathic pain with other interventions.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male or female patients aged ≥18 years.
* Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
* Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.

Exclusion Criteria:

* Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
* Patients who have received HAL at any time prior to screening.

Where this trial is running

Sheffield, Alabama and 23 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Chemotherapy Induced Neuropathic PainNeuropathic PainChemotherapyPainNeuropathyCancerCIPNCINP
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.